Who are CJ 0.9% Normal Saline Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard treatment with saline infusion, Plasma-lyte, Plasma-lyte (dynamic group), Plasma-lyte (static group), Physiological serum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cj-0-9-normal-saline-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CJ 0.9% Normal Saline Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CJ 0.9% Normal Saline Injection (CJ 0.9% Normal Saline Injection) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous fluid / Electrolyte replacement. Area: Supportive Care / Fluid Management.

phase 3 Intravenous fluid / Electrolyte replacement Supportive Care / Fluid Management Small molecule Live · refreshed every 30 min

Target snapshot

CJ 0.9% Normal Saline Injection (CJ 0.9% Normal Saline Injection) — Seoul National University Hospital. Normal saline (0.9% sodium chloride) provides isotonic fluid replacement and electrolyte balance for intravenous administration.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
CJ 0.9% Normal Saline Injection TARGET	CJ 0.9% Normal Saline Injection	Seoul National University Hospital	phase 3	Intravenous fluid / Electrolyte replacement
Standard treatment with saline infusion	Standard treatment with saline infusion	University of Roma La Sapienza	marketed	Intravenous fluid / electrolyte replacement
Plasma-lyte	Plasma-lyte	Fundación Santa Fe de Bogota	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution
Plasma-lyte (dynamic group)	Plasma-lyte (dynamic group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution
Plasma-lyte (static group)	Plasma-lyte (static group)	Algemeen Ziekenhuis Maria Middelares	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution
Physiological serum	Physiological serum	Hospital Clinic of Barcelona	marketed	Intravenous fluid / Electrolyte replacement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous fluid / Electrolyte replacement class)

Hospital Clinic of Barcelona · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CJ 0.9% Normal Saline Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/cj-0-9-normal-saline-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing